2014 -- S 2531 | |
======== | |
LC004021 | |
======== | |
STATE OF RHODE ISLAND | |
IN GENERAL ASSEMBLY | |
JANUARY SESSION, A.D. 2014 | |
____________ | |
A N A C T | |
RELATING TO INSURANCE -- PRESCRIPTION DRUG BENEFITS | |
| |
Introduced By: Senators Walaska, and McCaffrey | |
Date Introduced: February 27, 2014 | |
Referred To: Senate Health & Human Services | |
It is enacted by the General Assembly as follows: | |
1 | SECTION 1. Section 27-18-33 of the General Laws in Chapter 27-18 entitled "Accident |
2 | and Sickness Insurance Policies" is hereby amended to read as follows: |
3 | 27-18-33. Drug coverage. – (a) No group health insurer subject to the provisions of this |
4 | chapter that provides coverage for prescription drugs under a group plan master contract |
5 | delivered, issued for delivery, or renewed in this state may require any person covered under the |
6 | contract to obtain prescription drugs from a mail order pharmacy as a condition of obtaining |
7 | benefits for the drugs. |
8 | (b) No group health insurer shall refuse to contract with a qualified pharmacy provider |
9 | willing to meet the terms and conditions of the group health insurer for pharmacy participation. |
10 | (c) A group health insurer may not require a pharmacy provider to participate in one |
11 | network in order to participate in another network. The group health insurer may not exclude an |
12 | otherwise qualified pharmacy provider from participation in one network solely because the |
13 | pharmacy provider declined to participate in another network managed by the insurer. |
14 | This subsection shall not be construed to limit a group health insurer's ability to offer an |
15 | enrollee incentives, including variations in premiums, deductibles, copayments or coinsurance or |
16 | variations in the quantities of medications available to the enrollee, to encourage the use of |
17 | certain preferred pharmacy providers as long as the entity makes the terms applicable to the |
18 | preferred pharmacy providers available to all pharmacy providers. For purposes of this |
19 | subsection, a preferred pharmacy provider is any pharmacy willing to meet the specified terms, |
| |
1 | conditions and price that the carrier may require for its preferred pharmacy providers. |
2 | (d) The agreement between a group health insurer and a pharmacy provider shall not |
3 | require a pharmacy provider to assume liability for acts solely of the group health insurance |
4 | provider. |
5 | (e) Group health insurers shall distribute payments received for the services of a |
6 | pharmacy provider as required by law. |
7 | (f) No group health insurer shall terminate the contract of or penalize a pharmacy |
8 | provider solely as a result of the pharmacy provider's filing of a complaint, grievance or appeal. |
9 | Termination by mutual agreement shall not be restricted. |
10 | (g) No group health insurer shall terminate the contract of a pharmacy provider for |
11 | expressing disagreement with a group health insurer's decision to deny or limit benefits to an |
12 | enrollee, or because the pharmacy provider assists the enrollee to seek reconsideration of the |
13 | group health insurer's decision or because the pharmacy provider discusses alternative |
14 | medications. |
15 | (h) At least sixty (60) days before a group health insurer terminates a pharmacy |
16 | provider's participation in the plan or network, the group health insurer shall give the pharmacy |
17 | provider a written explanation of the reason for the termination, unless the termination is based on |
18 | either the loss of the pharmacy provider's license to practice pharmacy or cancellation of |
19 | professional liability insurance or a finding of fraud. |
20 | (i) Notwithstanding any other provision of law, when an on-site audit of the records of a |
21 | pharmacy provider is conducted by a group health insurer, the audit shall be conducted in |
22 | accordance with the following criteria: |
23 | (1) A finding of overpayment or underpayment must be based on the actual overpayment |
24 | or underpayment and not a projection based on the number of patients served having a similar |
25 | diagnosis or on the number of similar orders or refills for similar drugs, unless the projected |
26 | overpayment or denial is a part of a settlement agreed to by the pharmacy provider. |
27 | (2) The auditor may not use extrapolation in calculating recoupments or penalties. |
28 | (3) Any audit that involves clinical or professional judgment must be conducted by or in |
29 | consultation with a pharmacist. |
30 | (4) A group health insurer conducting an audit shall establish an appeals process under |
31 | which a pharmacy provider may appeal an unfavorable preliminary audit report to the insurer. |
32 | (5) This subsection shall not apply to any audit, review or investigation that is initiated |
33 | based on or involves suspected or alleged fraud, willful misrepresentation or abuse. |
34 | (6) A preliminary audit report must be delivered to the pharmacy provider within sixty |
| LC004021 - Page 2 of 15 |
1 | (60) days after the conclusion of the audit. A pharmacy provider must be allowed at least thirty |
2 | (30) days following receipt of the preliminary audit to provide documentation to address any |
3 | discrepancy found in the audit. A final audit report must be delivered to the pharmacy provider |
4 | within ninety (90) days after receipt of the preliminary audit report or final appeal, whichever is |
5 | later. A charge-back, recoupment or other penalty may not be assessed until the appeal process |
6 | provided by the pharmacy benefits manager has been exhausted and the final report issued. |
7 | Except as provided by state or federal law, audit information may not be shared. Auditors may |
8 | have access only to previous audit reports on a particular pharmacy provider conducted by that |
9 | same entity. |
10 | (7) Prior to an audit, the group health insurer conducting an audit shall give the pharmacy |
11 | provider ten (10) days' advance written notice of the audit and the range of prescription numbers |
12 | and the range of dates included in the audit. |
13 | (8) A pharmacy provider has the right to request mediation by a private mediator, agreed |
14 | upon by the pharmacy provider and the listed entity, to resolve any disagreement. A request for |
15 | mediation does not waive any existing rights of appeal available to a pharmacy provider. |
16 | (j) Maximum allowable cost provisions: |
17 | (1) "Maximum allowable cost" means the maximum amount that a pharmacy benefits |
18 | manager will pay toward the cost of a drug. |
19 | (2) "Nationally available" means that all pharmacies in this state can purchase the drug, |
20 | without limitation, from regional or national wholesalers and that the product is not obsolete or |
21 | temporarily available. |
22 | (3) "Therapeutically equivalent" means the drug is identified as therapeutically or |
23 | pharmaceutically equivalent or "A" rated by the United States Food and Drug Administration. |
24 | (4) A pharmacy benefits manager may not place a prescription drug on a maximum |
25 | allowable cost pricing index or create for a prescription drug a maximum allowable cost rate if |
26 | the prescription drug does not have three (3) or more nationally available and therapeutically |
27 | equivalent drug substitutes. |
28 | (5) A pharmacy benefits manager shall remove a prescription drug from a maximum |
29 | allowable cost pricing index, or modify maximum allowable cost rates, as such eliminations and |
30 | modifications are necessary to remain consistent with changes in the national marketplace for |
31 | prescription drugs. Eliminations and modifications made under this subsection must be made in a |
32 | timely fashion. |
33 | (6) A pharmacy benefits manager shall disclose to a pharmacy for which the pharmacy |
34 | benefits manager processes claims, makes payment of claims or procures drugs: |
| LC004021 - Page 3 of 15 |
1 | (i) At the beginning of each calendar year, the basis of the methodology and the sources |
2 | used to create the maximum allowable cost pricing index or maximum allowable cost rates used |
3 | by the pharmacy benefits manager. |
4 | (ii) At least once every seven (7) business days, the maximum allowable cost pricing |
5 | index or maximum allowable cost rates used by the pharmacy benefits manager. |
6 | (7) A pharmacy benefits manager shall give prompt written notification to a pharmacy |
7 | provider of any change made to a maximum allowable cost pricing index or maximum allowable |
8 | cost rates. |
9 | (8) A pharmacy benefits manager shall establish a procedure by which a pharmacy |
10 | provider may contest a maximum allowable cost rate. A procedure established under this |
11 | subsection must require a pharmacy benefits manager to respond to a pharmacy provider that has |
12 | contested a maximum allowable cost within fifteen (15) calendar days. If the pharmacy benefits |
13 | manager changes the rate, the change must: |
14 | (i) Become effective on the date on which the pharmacy provider initiated proceedings |
15 | under this subsection; and |
16 | (ii) Apply to all pharmacy providers in the network of pharmacy providers served by the |
17 | pharmacy benefits manager. |
18 | (9) A pharmacy benefits manager shall disclose to an insurance carrier, with which the |
19 | pharmacy benefits manager has entered into a contract: |
20 | (i) At the beginning of each calendar year, the basis of the methodology and the sources |
21 | used to create the maximum allowable cost pricing index or maximum allowable cost rates used |
22 | by the pharmacy benefits manager; |
23 | (ii) As soon as practicable, any change made to a maximum allowable cost pricing index |
24 | or maximum allowable cost rates; |
25 | (iii) Not later than twenty-one (21) business days after implementing the practice, the |
26 | utilization of a maximum allowable cost pricing index or maximum allowable cost rates for |
27 | prescription drugs dispensed at a retail community pharmacy provider; and |
28 | (iv) Whether the pharmacy benefits manager used identical maximum allowable cost |
29 | rates for billing the provider of the health benefit plan and for reimbursing a pharmacy provider |
30 | and, if the pharmacy benefits manager used different maximum allowable cost rates, the |
31 | difference between the amount billed and the amount reimbursed. |
32 | (k) The department of business regulation shall exercise oversight and enforcement of |
33 | this section. |
34 | SECTION 2. Section 27-19-26 of the General Laws in Chapter 27-19 entitled "Nonprofit |
| LC004021 - Page 4 of 15 |
1 | Hospital Service Corporations" is hereby amended to read as follows: |
2 | 27-19-26. Drug coverage. -- (a) No group health insurer subject to the provisions of this |
3 | chapter that provides coverage for prescription drugs under a group plan master contract |
4 | delivered, issued for delivery, or renewed in this state may require any person covered under the |
5 | contract to obtain prescription drugs from a mail order pharmacy as a condition of obtaining |
6 | benefits for the drugs. |
7 | (b) No nonprofit hospital service corporation shall refuse to contract with a qualified |
8 | pharmacy provider willing to meet the terms and conditions of the nonprofit hospital service |
9 | corporation for pharmacy participation. |
10 | (c) A nonprofit hospital service corporation may not require a pharmacy provider to |
11 | participate in one network in order to participate in another network. The nonprofit hospital |
12 | service corporation may not exclude an otherwise qualified pharmacy provider from participation |
13 | in one network solely because the pharmacy provider declined to participate in another network |
14 | managed by the insurer. |
15 | This subsection shall not be construed to limit a nonprofit hospital service corporation's |
16 | ability to offer an enrollee incentives, including variations in premiums, deductibles, copayments |
17 | or coinsurance or variations in the quantities of medications available to the enrollee, to |
18 | encourage the use of certain preferred pharmacy providers as long as the entity makes the terms |
19 | applicable to the preferred pharmacy providers available to all pharmacy providers. For purposes |
20 | of this subsection, a preferred pharmacy provider is any pharmacy willing to meet the specified |
21 | terms, conditions and price that the carrier may require for its preferred pharmacy providers. |
22 | (d) The agreement between a nonprofit hospital service corporation and a pharmacy |
23 | provider shall not require a pharmacy provider to assume liability for acts solely of the group |
24 | health insurance provider. |
25 | (e) Nonprofit hospital service corporations shall distribute payments received for the |
26 | services of a pharmacy provider as required by law. |
27 | (f) No nonprofit hospital service corporation shall terminate the contract of or penalize a |
28 | pharmacy provider solely as a result of the pharmacy provider's filing of a complaint, grievance, |
29 | or appeal. Termination by mutual agreement shall not be restricted. |
30 | (g) No nonprofit hospital service corporation shall terminate the contract of a pharmacy |
31 | provider for expressing disagreement with a nonprofit hospital service corporation's decision to |
32 | deny or limit benefits to an enrollee or because the pharmacy provider assists the enrollee to seek |
33 | reconsideration of the nonprofit hospital service corporation's decision or because the pharmacy |
34 | provider discusses alternative medications. |
| LC004021 - Page 5 of 15 |
1 | (h) At least sixty (60) days before a nonprofit hospital service corporation terminates a |
2 | pharmacy provider's participation in the plan or network, the nonprofit hospital service |
3 | corporation shall give the pharmacy provider a written explanation of the reason for the |
4 | termination, unless the termination is based on either the loss of the pharmacy provider's license |
5 | to practice pharmacy, or cancellation of professional liability insurance, or a finding of fraud. |
6 | (i) Notwithstanding any other provision of law, when an on-site audit of the records of a |
7 | pharmacy provider is conducted by a nonprofit hospital service corporation, the audit shall be |
8 | conducted in accordance with the following criteria: |
9 | (1) A finding of overpayment or underpayment must be based on the actual overpayment |
10 | or underpayment and not a projection based on the number of patients served having a similar |
11 | diagnosis or on the number of similar orders or refills for similar drugs, unless the projected |
12 | overpayment or denial is a part of a settlement agreed to by the pharmacy provider. |
13 | (2) The auditor may not use extrapolation in calculating recoupments or penalties. |
14 | (3) Any audit that involves clinical or professional judgment must be conducted by or in |
15 | consultation with a pharmacist. |
16 | (4) A nonprofit hospital service corporation conducting an audit shall establish an appeals |
17 | process under which a pharmacy provider may appeal an unfavorable preliminary audit report to |
18 | the insurer. |
19 | (5) This subsection shall not apply to any audit, review or investigation that is initiated |
20 | based on or involves suspected or alleged fraud, willful misrepresentation or abuse. |
21 | (6) A preliminary audit report must be delivered to the pharmacy provider within sixty |
22 | (60) days after the conclusion of the audit. A pharmacy provider must be allowed at least thirty |
23 | (30) days following receipt of the preliminary audit to provide documentation to address any |
24 | discrepancy found in the audit. A final audit report must be delivered to the pharmacy provider |
25 | within ninety (90) days after receipt of the preliminary audit report or final appeal, whichever is |
26 | later. A charge-back, recoupment or other penalty may not be assessed until the appeal process |
27 | provided by the pharmacy benefits manager has been exhausted and the final report issued. |
28 | Except as provided by state or federal law, audit information may not be shared. Auditors may |
29 | have access only to previous audit reports on a particular pharmacy provider conducted by that |
30 | same entity. |
31 | (7) Prior to an audit, the nonprofit hospital service corporation conducting an audit shall |
32 | give the pharmacy provider ten (10) days' advance written notice of the audit and the range of |
33 | prescription numbers and the range of dates included in the audit. |
34 | (8) A pharmacy provider has the right to request mediation by a private mediator, agreed |
| LC004021 - Page 6 of 15 |
1 | upon by the pharmacy and the listed entity, to resolve any disagreement. A request for mediation |
2 | does not waive any existing rights of appeal available to a pharmacy provider. |
3 | (j) Maximum allowable cost provisions: |
4 | (1) "Maximum allowable cost" means the maximum amount that a pharmacy benefits |
5 | manager will pay toward the cost of a drug. |
6 | (2) "Nationally available" means that all pharmacies in this state can purchase the drug, |
7 | without limitation, from regional or national wholesalers and that the product is not obsolete or |
8 | temporarily available. |
9 | (3) "Therapeutically equivalent" means the drug is identified as therapeutically or |
10 | pharmaceutically equivalent or "A" rated by the United States Food and Drug Administration. |
11 | (4) A pharmacy benefits manager may not place a prescription drug on a maximum |
12 | allowable cost pricing index or create for a prescription drug a maximum allowable cost rate if |
13 | the prescription drug does not have three (3) or more nationally available and therapeutically |
14 | equivalent drug substitutes. |
15 | (5) A pharmacy benefits manager shall remove a prescription drug from a maximum |
16 | allowable cost pricing index, or modify maximum allowable cost rates, as such eliminations and |
17 | modifications are necessary to remain consistent with changes in the national marketplace for |
18 | prescription drugs. Eliminations and modifications made under this subsection must be made in a |
19 | timely fashion. |
20 | (6) A pharmacy benefits manager shall disclose to a pharmacy for which the pharmacy |
21 | benefits manager processes claims, makes payment of claims or procures drugs: |
22 | (i) At the beginning of each calendar year, the basis of the methodology and the sources |
23 | used to create the maximum allowable cost pricing index or maximum allowable cost rates used |
24 | by the pharmacy benefits manager. |
25 | (ii) At least once every seven (7) business days, the maximum allowable cost pricing |
26 | index or maximum allowable cost rates used by the pharmacy benefits manager. |
27 | (7) A pharmacy benefits manager shall give prompt written notification to a pharmacy |
28 | provider of any change made to a maximum allowable cost pricing index or maximum allowable |
29 | cost rates. |
30 | (8) A pharmacy benefits manager shall establish a procedure by which a pharmacy |
31 | provider may contest a maximum allowable cost rate. A procedure established under this |
32 | subsection must require a pharmacy benefits manager to respond to a pharmacy provider that has |
33 | contested a maximum allowable cost within fifteen (15) calendar days. If the pharmacy benefits |
34 | manager changes the rate, the change must: |
| LC004021 - Page 7 of 15 |
1 | (i) Become effective on the date on which the pharmacy provider initiated proceedings |
2 | under this subsection; and |
3 | (ii) Apply to all pharmacy providers in the network of pharmacy providers served by the |
4 | pharmacy benefits manager. |
5 | (9) A pharmacy benefits manager shall disclose to an insurance carrier, with which the |
6 | pharmacy benefits manager has entered into a contract: |
7 | (i) At the beginning of each calendar year, the basis of the methodology and the sources |
8 | used to create the maximum allowable cost pricing index or maximum allowable cost rates used |
9 | by the pharmacy benefits manager; |
10 | (ii) As soon as practicable, any change made to a maximum allowable cost pricing index |
11 | or maximum allowable cost rates; |
12 | (iii) Not later than twenty-one (21) business days after implementing the practice, the |
13 | utilization of a maximum allowable cost pricing index or maximum allowable cost rates for |
14 | prescription drugs dispensed at a retail community pharmacy; and |
15 | (iv) Whether the pharmacy benefits manager used identical maximum allowable cost |
16 | rates for billing the provider of the health benefit plan and for reimbursing a pharmacy provider |
17 | and, if the pharmacy benefits manager used different maximum allowable cost rates, the |
18 | difference between the amount billed and the amount reimbursed. |
19 | (k) The department of business regulation shall exercise oversight and enforcement of |
20 | this section. |
21 | SECTION 3. Section 27-20-23 of the General Laws in Chapter 27-20 entitled "Nonprofit |
22 | Medical Service Corporations" is hereby amended to read as follows: |
23 | 27-20-23. Drug coverage. -- (a) No group health insurer subject to the provisions of this |
24 | chapter that provides coverage for prescription drugs under a group plan master contract |
25 | delivered, issued for delivery, or renewed in this state may require any person covered under the |
26 | contract to obtain prescription drugs from a mail order pharmacy as a condition of obtaining |
27 | benefits for the drugs. |
28 | (b) No nonprofit medical service corporation shall refuse to contract with a qualified |
29 | pharmacy provider willing to meet the terms and conditions of the nonprofit medical service |
30 | corporation for pharmacy participation. |
31 | (c) A nonprofit medical service corporation may not require a pharmacy provider to |
32 | participate in one network in order to participate in another network. The nonprofit medical |
33 | service corporation may not exclude an otherwise qualified pharmacy provider from participation |
34 | in one network solely because the pharmacy provider declined to participate in another network |
| LC004021 - Page 8 of 15 |
1 | managed by the insurer. |
2 | This subsection shall not be construed to limit a nonprofit medical service corporation's |
3 | ability to offer an enrollee incentives, including variations in premiums, deductibles, copayments |
4 | or coinsurance or variations in the quantities of medications available to the enrollee, to |
5 | encourage the use of certain preferred pharmacy providers as long as the entity makes the terms |
6 | applicable to the preferred pharmacy providers available to all pharmacy providers. For purposes |
7 | of this subsection, a preferred pharmacy provider is any pharmacy willing to meet the specified |
8 | terms, conditions and price that the carrier may require for its preferred pharmacy providers. |
9 | (d) The agreement between a nonprofit medical service corporation and a pharmacy |
10 | provider shall not require a pharmacy provider to assume liability for acts solely of the group |
11 | health insurance provider. |
12 | (e) Nonprofit medical service corporations shall distribute payments received for the |
13 | services of a pharmacy provider as required by law. |
14 | (f) No nonprofit medical service corporation shall terminate the contract of or penalize a |
15 | pharmacy provider solely as a result of the pharmacy provider's filing of a complaint, grievance |
16 | or appeal. Termination by mutual agreement shall not be restricted. |
17 | (g) No nonprofit medical service corporation shall terminate the contract of a pharmacy |
18 | provider for expressing disagreement with a nonprofit medical service corporation's decision to |
19 | deny or limit benefits to an enrollee or because the pharmacy provider assists the enrollee to seek |
20 | reconsideration of the nonprofit medical service corporation's decision or because the pharmacy |
21 | provider discusses alternative medications. |
22 | (h) At least sixty (60) days before a nonprofit medical service corporation terminates a |
23 | pharmacy provider's participation in the plan or network, the nonprofit medical service |
24 | corporation shall give the pharmacy provider a written explanation of the reason for the |
25 | termination, unless the termination is based on either the loss of the pharmacy provider's license |
26 | to practice pharmacy or cancellation of professional liability insurance or a finding of fraud. |
27 | (i) Notwithstanding any other provision of law, when an on-site audit of the records of a |
28 | pharmacy provider is conducted by a nonprofit medical service corporation, the audit shall be |
29 | conducted in accordance with the following criteria: |
30 | (1) A finding of overpayment or underpayment must be based on the actual overpayment |
31 | or underpayment and not a projection based on the number of patients served having a similar |
32 | diagnosis or on the number of similar orders or refills for similar drugs, unless the projected |
33 | overpayment or denial is a part of a settlement agreed to by the pharmacy provider. |
34 | (2) The auditor may not use extrapolation in calculating recoupments or penalties. |
| LC004021 - Page 9 of 15 |
1 | (3) Any audit that involves clinical or professional judgment must be conducted by or in |
2 | consultation with a pharmacist. |
3 | (4) A nonprofit medical service corporation conducting an audit shall establish an appeals |
4 | process under which a pharmacy provider may appeal an unfavorable preliminary audit report to |
5 | the insurer. |
6 | (5) This subsection shall not apply to any audit, review or investigation that is initiated |
7 | based on or involves suspected or alleged fraud, willful misrepresentation or abuse. |
8 | (6) A preliminary audit report must be delivered to the pharmacy provider within sixty |
9 | (60) days after the conclusion of the audit. A pharmacy provider must be allowed at least thirty |
10 | (30) days following receipt of the preliminary audit to provide documentation to address any |
11 | discrepancy found in the audit. A final audit report must be delivered to the pharmacy provider |
12 | within ninety (90) days after receipt of the preliminary audit report or final appeal, whichever is |
13 | later. A charge-back, recoupment or other penalty may not be assessed until the appeal process |
14 | provided by the pharmacy benefits manager has been exhausted and the final report issued. |
15 | Except as provided by state or federal law, audit information may not be shared. Auditors may |
16 | have access only to previous audit reports on a particular pharmacy provider conducted by that |
17 | same entity. |
18 | (7) Prior to an audit, the nonprofit medical service corporation conducting an audit shall |
19 | give the pharmacy provider ten (10) days' advance written notice of the audit and the range of |
20 | prescription numbers and the range of dates included in the audit. |
21 | (8) A pharmacy provider has the right to request mediation by a private mediator, agreed |
22 | upon by the pharmacy provider and the listed entity, to resolve any disagreement. A request for |
23 | mediation does not waive any existing rights of appeal available to a pharmacy provider. |
24 | (j) Maximum allowable cost provisions: |
25 | (1) "Maximum allowable cost" means the maximum amount that a pharmacy benefits |
26 | manager will pay toward the cost of a drug. |
27 | (2) "Nationally available" means that all pharmacies in this state can purchase the drug, |
28 | without limitation, from regional or national wholesalers and that the product is not obsolete or |
29 | temporarily available. |
30 | (3) "Therapeutically equivalent" means the drug is identified as therapeutically or |
31 | pharmaceutically equivalent or "A" rated by the United States Food and Drug Administration. |
32 | (4) A pharmacy benefits manager may not place a prescription drug on a maximum |
33 | allowable cost pricing index or create for a prescription drug a maximum allowable cost rate if |
34 | the prescription drug does not have three (3) or more nationally available and therapeutically |
| LC004021 - Page 10 of 15 |
1 | equivalent drug substitutes. |
2 | (5) A pharmacy benefits manager shall remove a prescription drug from a maximum |
3 | allowable cost pricing index, or modify maximum allowable cost rates, as such eliminations and |
4 | modifications are necessary to remain consistent with changes in the national marketplace for |
5 | prescription drugs. Eliminations and modifications made under this subsection must be made in a |
6 | timely fashion. |
7 | (6) A pharmacy benefits manager shall disclose to a pharmacy provider for which the |
8 | pharmacy benefits manager processes claims, makes payment of claims or procures drugs: |
9 | (i) At the beginning of each calendar year, the basis of the methodology and the sources |
10 | used to create the maximum allowable cost pricing index or maximum allowable cost rates used |
11 | by the pharmacy benefits manager. |
12 | (ii) At least once every seven (7) business days, the maximum allowable cost pricing |
13 | index or maximum allowable cost rates used by the pharmacy benefits manager. |
14 | (7) A pharmacy benefits manager shall give prompt written notification to a pharmacy |
15 | provider of any change made to a maximum allowable cost pricing index or maximum allowable |
16 | cost rates. |
17 | (8) A pharmacy benefits manager shall establish a procedure by which a pharmacy |
18 | provider may contest a maximum allowable cost rate. A procedure established under this |
19 | subsection must require a pharmacy benefits manager to respond to a pharmacy provider that has |
20 | contested a maximum allowable cost within fifteen (15) calendar days. If the pharmacy benefits |
21 | manager changes the rate, the change must: |
22 | (i) Become effective on the date on which the pharmacy provider initiated proceedings |
23 | under this subsection; and |
24 | (ii) Apply to all pharmacy providers in the network of pharmacy providers served by the |
25 | pharmacy benefits manager. |
26 | (9) A pharmacy benefits manager shall disclose to an insurance carrier, with which the |
27 | pharmacy benefits manager has entered into a contract: |
28 | (i) At the beginning of each calendar year, the basis of the methodology and the sources |
29 | used to create the maximum allowable cost pricing index or maximum allowable cost rates used |
30 | by the pharmacy benefits manager; |
31 | (ii) As soon as practicable, any change made to a maximum allowable cost pricing index |
32 | or maximum allowable cost rates; |
33 | (iii) Not later than twenty-one (21) business days after implementing the practice, the |
34 | utilization of a maximum allowable cost pricing index or maximum allowable cost rates for |
| LC004021 - Page 11 of 15 |
1 | prescription drugs dispensed at a retail community pharmacy; and |
2 | (iv) Whether the pharmacy benefits manager used identical maximum allowable cost |
3 | rates for billing the provider of the health benefit plan and for reimbursing a pharmacy provider |
4 | and, if the pharmacy benefits manager used different maximum allowable cost rates, the |
5 | difference between the amount billed and the amount reimbursed. |
6 | (k) The department of business regulation shall exercise oversight and enforcement of |
7 | this section. |
8 | SECTION 4. Section 27-41-38 of the General Laws in Chapter 27-41 entitled "Health |
9 | Maintenance Organizations" is hereby amended to read as follows: |
10 | 27-41-38. Drug coverage. -- (a) No group health insurer subject to the provisions of this |
11 | chapter that provides coverage for prescription drugs under a group plan master contract |
12 | delivered, issued for delivery, or renewed in this state may require any person covered under the |
13 | contract to obtain prescription drugs from a mail order pharmacy as a condition of obtaining |
14 | benefits for the drugs. |
15 | (b) No health maintenance organization shall refuse to contract with a qualified pharmacy |
16 | provider willing to meet the terms and conditions of the health maintenance organization for |
17 | pharmacy participation. |
18 | (c) A health maintenance organization may not require a pharmacy provider to participate |
19 | in one network in order to participate in another network. The health maintenance organization |
20 | may not exclude an otherwise qualified pharmacy provider from participation in one network |
21 | solely because the pharmacy provider declined to participate in another network managed by the |
22 | insurer. |
23 | This subsection shall not be construed to limit a health maintenance organization's ability |
24 | to offer an enrollee incentives, including variations in premiums, deductibles, copayments or |
25 | coinsurance or variations in the quantities of medications available to the enrollee, to encourage |
26 | the use of certain preferred pharmacy providers as long as the entity makes the terms applicable |
27 | to the preferred pharmacy providers available to all pharmacy providers. For purposes of this |
28 | subsection, a preferred pharmacy provider is any pharmacy willing to meet the specified terms, |
29 | conditions and price that the carrier may require for its preferred pharmacy providers. |
30 | (d) The agreement between a health maintenance organization and a pharmacy provider |
31 | shall not require a pharmacy provider to assume liability for acts solely of the group health |
32 | insurance provider. |
33 | (e) Health maintenance organizations shall distribute payments received for the services |
34 | of a pharmacy provider as required by law. |
| LC004021 - Page 12 of 15 |
1 | (f) No health maintenance organization shall terminate the contract of or penalize a |
2 | pharmacy provider solely as a result of the pharmacy provider's filing of a complaint, grievance, |
3 | or appeal. Termination by mutual agreement shall not be restricted. |
4 | (g) No health maintenance organization shall terminate the contract of a pharmacy |
5 | provider for expressing disagreement with a health maintenance organization's decision to deny |
6 | or limit benefits to an enrollee or because the pharmacy provider assists the enrollee to seek |
7 | reconsideration of the health maintenance organization's decision or because the pharmacy |
8 | provider discusses alternative medications. |
9 | (h) At least sixty (60) days before a health maintenance organization terminates a |
10 | pharmacy provider's participation in the plan or network, the health maintenance organization |
11 | shall give the pharmacy provider a written explanation of the reason for the termination, unless |
12 | the termination is based on either the loss of the pharmacy provider's license to practice pharmacy |
13 | or cancellation of professional liability insurance or a finding of fraud. |
14 | (i) Notwithstanding any other provision of law, when an on-site audit of the records of a |
15 | pharmacy provider is conducted by a health maintenance organization, the audit shall be |
16 | conducted in accordance with the following criteria: |
17 | (1) A finding of overpayment or underpayment must be based on the actual overpayment |
18 | or underpayment and not a projection based on the number of patients served having a similar |
19 | diagnosis or on the number of similar orders or refills for similar drugs, unless the projected |
20 | overpayment or denial is a part of a settlement agreed to by the pharmacy provider. |
21 | (2) The auditor may not use extrapolation in calculating recoupments or penalties. |
22 | (3) Any audit that involves clinical or professional judgment must be conducted by or in |
23 | consultation with a pharmacist. |
24 | (4) A health maintenance organization conducting an audit shall establish an appeals |
25 | process under which a pharmacy provider may appeal an unfavorable preliminary audit report to |
26 | the insurer. |
27 | (5) This subsection shall not apply to any audit, review or investigation that is initiated |
28 | based on or involves suspected or alleged fraud, willful misrepresentation or abuse. |
29 | (6) A preliminary audit report must be delivered to the pharmacy provider within sixty |
30 | (60) days after the conclusion of the audit. A pharmacy provider must be allowed at least thirty |
31 | (30) days following receipt of the preliminary audit to provide documentation to address any |
32 | discrepancy found in the audit. A final audit report must be delivered to the pharmacy provider |
33 | within ninety (90) days after receipt of the preliminary audit report or final appeal, whichever is |
34 | later. A charge-back, recoupment or other penalty may not be assessed until the appeal process |
| LC004021 - Page 13 of 15 |
1 | provided by the pharmacy benefits manager has been exhausted and the final report issued. |
2 | Except as provided by state or federal law, audit information may not be shared. Auditors may |
3 | have access only to previous audit reports on a particular pharmacy provider conducted by that |
4 | same entity. |
5 | (7) Prior to an audit, the health maintenance organization conducting an audit shall give |
6 | the pharmacy provider ten (10) days' advance written notice of the audit and the range of |
7 | prescription numbers and the range of dates included in the audit. |
8 | (8) A pharmacy provider has the right to request mediation by a private mediator, agreed |
9 | upon by the pharmacy provider and the listed entity, to resolve any disagreement. A request for |
10 | mediation does not waive any existing rights of appeal available to a pharmacy provider. |
11 | (j) Maximum allowable cost provisions: |
12 | (1) "Maximum allowable cost" means the maximum amount that a pharmacy benefits |
13 | manager will pay toward the cost of a drug. |
14 | (2) "Nationally available" means that all pharmacies in this state can purchase the drug, |
15 | without limitation, from regional or national wholesalers and that the product is not obsolete or |
16 | temporarily available. |
17 | (3) "Therapeutically equivalent" means the drug is identified as therapeutically or |
18 | pharmaceutically equivalent or "A" rated by the United States Food and Drug Administration. |
19 | (4) A pharmacy benefits manager may not place a prescription drug on a maximum |
20 | allowable cost pricing index or create for a prescription drug a maximum allowable cost rate if |
21 | the prescription drug does not have three (3) or more nationally available and therapeutically |
22 | equivalent drug substitutes. |
23 | (5) A pharmacy benefits manager shall remove a prescription drug from a maximum |
24 | allowable cost pricing index, or modify maximum allowable cost rates, as such eliminations and |
25 | modifications are necessary to remain consistent with changes in the national marketplace for |
26 | prescription drugs. Eliminations and modifications made under this subsection must be made in a |
27 | timely fashion. |
28 | (6) A pharmacy benefits manager shall disclose to a pharmacy provider for which the |
29 | pharmacy benefits manager processes claims, makes payment of claims or procures drugs: |
30 | (i) At the beginning of each calendar year, the basis of the methodology and the sources |
31 | used to create the maximum allowable cost pricing index or maximum allowable cost rates used |
32 | by the pharmacy benefits manager. |
33 | (ii) At least once every seven (7) business days, the maximum allowable cost pricing |
34 | index or maximum allowable cost rates used by the pharmacy benefits manager. |
| LC004021 - Page 14 of 15 |
1 | (7) A pharmacy benefits manager shall give prompt written notification to a pharmacy |
2 | provider of any change made to a maximum allowable cost pricing index or maximum allowable |
3 | cost rates. |
4 | (8) A pharmacy benefits manager shall establish a procedure by which a pharmacy |
5 | provider may contest a maximum allowable cost rate. A procedure established under this |
6 | subsection must require a pharmacy benefits manager to respond to a pharmacy provider that has |
7 | contested a maximum allowable cost within fifteen (15) calendar days. If the pharmacy benefits |
8 | manager changes the rate, the change must: |
9 | (i) Become effective on the date on which the pharmacy provider initiated proceedings |
10 | under this subsection; and |
11 | (ii) Apply to all pharmacy providers in the network of pharmacy providers served by the |
12 | pharmacy benefits manager. |
13 | (9) A pharmacy benefits manager shall disclose to an insurance carrier, with which the |
14 | pharmacy benefits manager has entered into a contract: |
15 | (i) At the beginning of each calendar year, the basis of the methodology and the sources |
16 | used to create the maximum allowable cost pricing index or maximum allowable cost rates used |
17 | by the pharmacy benefits manager; |
18 | (ii) As soon as practicable, any change made to a maximum allowable cost pricing index |
19 | or maximum allowable cost rates; |
20 | (iii) Not later than twenty-one (21) business days after implementing the practice, the |
21 | utilization of a maximum allowable cost pricing index or maximum allowable cost rates for |
22 | prescription drugs dispensed at a retail community pharmacy; and |
23 | (iv) Whether the pharmacy benefits manager used identical maximum allowable cost |
24 | rates for billing the provider of the health benefit plan and for reimbursing a pharmacy provider |
25 | and, if the pharmacy benefits manager used different maximum allowable cost rates, the |
26 | difference between the amount billed and the amount reimbursed. |
27 | (k) The department of business regulation shall exercise oversight and enforcement of |
28 | this section. |
29 | SECTION 5. This act shall take effect upon passage. |
======== | |
LC004021 | |
======== | |
| LC004021 - Page 15 of 15 |
EXPLANATION | |
BY THE LEGISLATIVE COUNCIL | |
OF | |
A N A C T | |
RELATING TO INSURANCE -- PRESCRIPTION DRUG BENEFITS | |
*** | |
1 | This act would regulate the business relationship between providers of pharmacy services |
2 | and group health insurers, nonprofit hospital service corporations, nonprofit medical service |
3 | corporations and health maintenance organizations including establishment of the relationship |
4 | and the requirements needed to be considered an acceptable pharmacy service provider, |
5 | termination of the relationship, audits, acceptance or denial of benefits, substitution of drugs with |
6 | therapeutic equivalents, cost limitations, maximum allowable cost rates and grievance procedures |
7 | between the parties, and liability sharing requirements. |
8 | The department of business regulation is declared the state agency in charge of oversight |
9 | of the business relationship between pharmacy providers and health service organizations. |
10 | This act would take effect upon passage. |
======== | |
LC004021 | |
======== | |
| LC004021 - Page 16 of 15 |